Epizyme content uploads

A Phase 1 Study of Tazemetostat (EPZ-6438), an Enhancer of Zeste ... » Sep 26, 2015 ...A Italiano, H Keilhack, M Toulmonde, J-M Coindre, J-M Michot, C Massard,. L Ottesen, L Reyderman, SJ Blakemore, S Kraljevic, B Thomson, A McDonald,. PT Ho, J-C Soria, V Ribrag. Participating Institutions. Insitut Gustave Roussy, Villejuif , France. Institut Bergonie, Bourdeaux, France. Sponsor. Epizyme... Epizyme.com

Epizyme shares slump as cancer drug data update disappoints ... » Jun 14, 2017 ...Analysts hate to be disappointed, and that's just what Epizyme $EPZM accomplished this morning as it updated its camp followers with the latest data on tazemetostat for diffuse large B-cell lymphoma. Initially, observers had been pleased by the 40% overall response rate that researchers had been tracking... Endpts.com

histone methyl transferase inhibitor E7438 as a single agent in ... » Nov 20, 2014 ...Disclosures. • VR: Advisory board, Eisai Inc. • JCS: Nothing to disclose. • AI: Honoraria–GlaxoSmithKline, Pfizer,. PHarmaMar; Threshold Research Funding–. Novartis, Pfizer, PharmaMar, Roche. • LR, RC, PS, NK, GK, and LHO are employees of Eisai Inc. • HK is an employee of Epizyme Inc. 3... Epizyme.com

SCCOHT » Mar 11, 2016 ...www.epizyme.com. 30 Ovarian cell lines were characterized for SMARCA2, SMARCB1, and SMARCA4 protein levels. In addi on to Bin-‐67, two addi onal SCCOHT cell lines, TOV112D and COV434, were iden fied based on the dual loss of SMARCA2 and SMARCA4 expression. Muta ons were taken from... Epizyme.com

Tazemetostat Phase 1 NHL Update at ASH Lymphoma » Jun 21, 2016 ......Bijou, Jean-Michele Coindre,. Maud Toulemonde, Stephen J Blakemore, Ben Suttle, Scott Ribich,. Blythe Thomson, John Larus, Harry Miao, Peter TC Ho, and Antoine Italiano. Participating Institutions. Institut Gustave Roussy, Villejuif, France. Institut Bergonie, Bordeaux, France. Sponsor. Epizyme, Inc... Epizyme.com

BioCentury Innovations » Jan 15, 2015 ...6 EPIZYME'S MANTLE PIECE. Epizyme adds PRMT5 to the list of epigenetic targets and believes it has a first-in-class inhibitor of the enzyme. TOOLS & TECHNIQUES. 9 BOOSTING IgG WITH IgA. A UT Austin team has engineered chimeric mAbs that induce more potent leukocyte-mediated killing of. C-path.org

Epizyme Announces Additional Positive Data from Ongoing Phase 1 ... » Jun 20, 2015 ...Epizyme Announces Additional Positive Data from Ongoing Phase 1 Study of Tazemetostat. (EPZ-6438) in Relapsed or Refractory Non-Hodgkin Lymphoma q. Objective responses seen in nine of 15 evaluable relapsed non-Hodgkin lymphoma (NHL) patients; five responders remain on study q. First treated... Files.shareholder.com

Your Daily Pharma Scoop: Gilead's Unappreciated Opportunity ... » Oct 30, 2017 ...Gilead's NASH and CAR-T assets are not being assigned any value by the market. Merck's MAA to the EMA for Keytruda in first line NSCLC withdrawn. Epizyme's taze. Seekingalpha.com

Epizyme's (EPZM) Positive Cancer Drug Results Likely to Catch the ... » Jun 15, 2017 ...Epizyme sank almost 20% since their last earnings report, but recent developments show positive data from one of its keynote drugs, Tazemetostat... EPZM. Thestreet.com

Epizyme, Inc. (EPZM) Stock Message Board - InvestorsHub » http://www.epizyme.com Overview & History Epizyme is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative personalized therapeutics for patients with genetically defined cancers . We systematically identify the genetic alterations that create cancer causing genes,... Investorshub.advfn.com